DE60322267D1 - Chinolinderivate als glucokinase liganden - Google Patents

Chinolinderivate als glucokinase liganden

Info

Publication number
DE60322267D1
DE60322267D1 DE60322267T DE60322267T DE60322267D1 DE 60322267 D1 DE60322267 D1 DE 60322267D1 DE 60322267 T DE60322267 T DE 60322267T DE 60322267 T DE60322267 T DE 60322267T DE 60322267 D1 DE60322267 D1 DE 60322267D1
Authority
DE
Germany
Prior art keywords
gluccokinase
ligands
sup
chinoline derivatives
chinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60322267T
Other languages
German (de)
English (en)
Inventor
Rodney Brian Hargreaves
Christopher Daniel Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60322267D1 publication Critical patent/DE60322267D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60322267T 2002-11-19 2003-11-13 Chinolinderivate als glucokinase liganden Expired - Fee Related DE60322267D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226931.4A GB0226931D0 (en) 2002-11-19 2002-11-19 Chemical compounds
PCT/GB2003/004915 WO2004045614A1 (en) 2002-11-19 2003-11-13 Quinoline derivatives as glucokinase ligands

Publications (1)

Publication Number Publication Date
DE60322267D1 true DE60322267D1 (de) 2008-08-28

Family

ID=9948090

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322267T Expired - Fee Related DE60322267D1 (de) 2002-11-19 2003-11-13 Chinolinderivate als glucokinase liganden

Country Status (9)

Country Link
US (1) US7230108B2 (enExample)
EP (1) EP1583532B1 (enExample)
JP (1) JP2006514626A (enExample)
AT (1) ATE401076T1 (enExample)
AU (1) AU2003282233A1 (enExample)
DE (1) DE60322267D1 (enExample)
ES (1) ES2307992T3 (enExample)
GB (1) GB0226931D0 (enExample)
WO (1) WO2004045614A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
FR2864535B1 (fr) 2003-12-24 2006-12-22 Merck Sante Sas Derives acides de quinoline et leurs applications en therapeutique
EP2048137A1 (en) * 2004-02-18 2009-04-15 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents.
JP2007523905A (ja) * 2004-02-18 2007-08-23 アストラゼネカ アクチボラグ 化合物
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
BRPI0516595A (pt) * 2004-10-16 2008-09-23 Astrazeneca Ab processo para fabricar um composto, e, composto
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
EP1891069A1 (en) * 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
KR20110084339A (ko) * 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
WO2007017649A1 (en) * 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
EP1948652B1 (en) * 2005-11-01 2011-08-24 Array Biopharma, Inc. Glucokinase activators
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
EP2010520B1 (en) * 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) * 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
MX2009006729A (es) 2006-12-21 2009-08-07 Astrazeneca Ab Nuevo compuesto cristalino util como activador de glk.
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
MX2011001333A (es) 2008-08-04 2011-03-15 Astrazeneca Ab Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
PL2424529T3 (pl) 2009-04-30 2017-06-30 Midwestern University Nowe postępowania terapeutyczne z zastosowaniem centakwiny
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012158474A1 (en) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10189788B2 (en) 2014-09-09 2019-01-29 Bayer Pharma Aktiengesellschaft Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
PE20191616A1 (es) 2017-04-10 2019-11-05 Bayer Ag N-ariletil-2-arilquinolina-4-carboxamidas sustituidas y su uso
CN112469474A (zh) 2018-05-03 2021-03-09 美国中西部大学 出血和centhaquin引起的复苏后内皮素受体的变化

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561350A (en) * 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
US5792109A (en) 1994-09-01 1998-08-11 Leland L. Ladd Irrigation pump and system
JPH08301760A (ja) 1995-05-10 1996-11-19 Shiseido Co Ltd 皮膚外用剤
JP3168915B2 (ja) 1995-05-25 2001-05-21 田辺製薬株式会社 医薬組成物
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
HK1046139B (zh) * 1999-03-29 2004-12-10 霍夫曼-拉罗奇有限公司 葡糖激酶活化剂
GB9921684D0 (en) 1999-09-15 1999-11-17 Zeneca Ltd Assays
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
EP1282612B1 (en) 2000-05-03 2004-12-29 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
ATE304011T1 (de) 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren
BR0110704A (pt) 2000-05-08 2003-01-28 Hoffmann La Roche Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
MXPA02010795A (es) 2000-05-08 2003-03-27 Hoffmann La Roche Activadores de glucocinasa de fenilamida sustituida por para-amino.
HK1052351B (en) 2000-06-28 2006-11-03 Japan Tobacco Inc. Benzothiazolyl ppar-gamma modulators
CA2416229C (en) 2000-07-20 2007-09-18 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
US7053105B2 (en) 2000-09-25 2006-05-30 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
EP1341774B1 (en) * 2000-12-06 2006-02-01 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
CA2460075A1 (en) 2001-09-12 2003-03-20 Donn Gregory Wishka Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
US7544690B2 (en) 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
EP1453541A1 (en) 2001-12-03 2004-09-08 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
EP1336607A1 (en) 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
KR101018318B1 (ko) 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Ｇｋ 활성제로서의 아미드 유도체
WO2003080585A1 (en) 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
CN100357283C (zh) 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
BR0309546A (pt) 2002-04-26 2005-02-15 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
AU2003235307A1 (en) 2002-05-16 2003-12-02 Banyu Pharmaceutical Co., Ltd. Crystal of glucokinase protein, and method for drug design using the crystal
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
ES2293005T3 (es) 2002-10-03 2008-03-16 F. Hoffmann-La Roche Ag Indol-3-carboxamidas como activadores de la glucocinasa.
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063179A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2004063194A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
WO2004076420A1 (ja) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
GB0327760D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0328178D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
US7728025B2 (en) 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
JP2007523905A (ja) 2004-02-18 2007-08-23 アストラゼネカ アクチボラグ 化合物
EP2048137A1 (en) 2004-02-18 2009-04-15 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents.
AU2005223610B2 (en) 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
US7781451B2 (en) 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
EA012204B1 (ru) 2004-04-21 2009-08-28 Прозидион Лимитед Три(цикло)замещённые амидные соединения
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
EP1758611A2 (en) 2004-06-17 2007-03-07 Novo Nordisk A/S Use of liver-selective glucokinase activators
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
BRPI0516595A (pt) 2004-10-16 2008-09-23 Astrazeneca Ab processo para fabricar um composto, e, composto
GB0423043D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds

Also Published As

Publication number Publication date
EP1583532A1 (en) 2005-10-12
US7230108B2 (en) 2007-06-12
US20060079553A1 (en) 2006-04-13
WO2004045614A1 (en) 2004-06-03
ATE401076T1 (de) 2008-08-15
EP1583532B1 (en) 2008-07-16
JP2006514626A (ja) 2006-05-11
ES2307992T3 (es) 2008-12-01
AU2003282233A1 (en) 2004-06-15
GB0226931D0 (en) 2002-12-24

Similar Documents

Publication Publication Date Title
ATE401076T1 (de) Chinolinderivate als glucokinase liganden
GB0226930D0 (en) Chemical compounds
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
DE60121931D1 (de) Chinazolinverbindungen
DE60215814D1 (de) Vinylphenyl-derivate als glk-aktivatoren
ATE264846T1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
ATE302775T1 (de) Carbolinderivate
SE0102300D0 (sv) Compounds
DK0863875T3 (da) Hidtil ukendte 4-(oxyalkoxyphenyl)-3-oxy-piperiner til behandling af hjerte- og nyrelidelser
ATE401314T1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
YU49443B (sh) Derivati benzimidazola, postupci za njihovo pripremanje i primena tih derivata u medicinskoj terapiji, naročito za lečenje ili sprečavanje virusnih infekcija
EA200300323A1 (ru) ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
ATE346067T1 (de) Carbolinderivate
ATE341545T1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE60119368D1 (de) Zusammensetzung enthaltend einen angiotensin-ii-rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
DE60128100D1 (de) Analgetisches arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee